United States· US:73372-0116_5192f26d-d5e7-ce03-e063-6294a90a3ea2

SCENESSE

A afamelanotide product containing afamelanotide, registered in United States by CLINUVEL INC.. The same ATC class is registered in 10 of our 19 countries.

ATC D02BB02US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedSCENESSEATCD02BB02REGISTER NO.US:73372-0116_5192f26…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Afamelanotide is registered in 10 of 19 countries.

Countries holding a registration under ATC D02BB02 (afamelanotide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 6 of them publish a price we can compare per daily dose

Afamelanotide · ATC D02BB02

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
AFAMELANOTIDE
Manufacturer
CLINUVEL INC.
Country
United States (US)
ATC code
D02BB02
ATC class
Afamelanotide
Defined daily dose
0.00822 DE, Implantat
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    7337201161
    1 VIAL, GLASS in 1 CARTON (73372-0116-1) / 1 mg in 1 VIAL, GLASS
  • ndc11
    73372-0116-1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Afamelanotide in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All afamelanotide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Scenesse
  • Liechtenstein · Scenesse
  • Norway · Scenesse

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e8eb21ed-49aa-4529-aac3-70c86f867184
GET /v1/drugs/e8eb21ed-49aa-4529-aac3-70c86f867184?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "16",
  "substance": "AFAMELANOTIDE",
  "productndc": "73372-0116",
  "dosage_form": "IMPLANT",
  "dea_schedule": null,
  "strength_unit": "mg/16mg",
  "application_number": "NDA210797",
  "marketing_category": "NDA"
}

See everything about afamelanotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.